NL-OMON42663已完成不适用
Validation hepatotoxicity-predictor-algorithm for patients with thiopurine drugs; A prospective observational study - Validation hepatotoxicity-predictor-algorithm for thiopurine drugs
Zuyderland Medisch Centrum0 个研究点目标入组 250 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •age > 18 years
- •patient agrees to take part in the study (signed informed consent)
- •Diagnosis: IBD (UC, CD, IBD-UC)
- •patients that start with thiopurine drugs (azathioprine or mercaptopurine)
排除标准
- •Known hypersensitivity to active substance or any of the excipients
- •Leukocytes <3 x 10^9 /l on baseline
- •Hepatic impairment at baseline (AST, ALT, y Gt or AF >= 2x upper normal range)
- •Reduced renal function at baseline (creatinine >= 2x upper normal range MDRD> 60ml / min)
研究者
相似试验
尚未招募
不适用
Validation hepatotoxicity-predictor-algorithm for patients with thiopurine drugs; A prospective observational studythiopurine drugshepatotoxicityNL-OMON26269n.a.200
已完成
不适用
iver safety analysis of Samsamani Vati/ Giloya ghana vati .CTRI/2022/06/043050JSS Ayurveda College30
招募中
不适用
Model development for the prediction of toxicity and prognosis in Korean elderly cancer patients receiving chemotherapy: a multicenter prospective studyKCT0001071Seoul National University Bundang Hospital200
已完成
不适用
PREDICTION OF RESPONSE AND TOXICITY IN PATIENTS WHO RECEIVE CHEMOTHERAPY FOR BREAST CANCER, CORRELATIVE STUDY OF GENOMICS, PROTEOMICS AND PHARMACOGENOMY-C509 Breast, unspecifiedBreast, unspecifiedC509PER-079-05HOSSIER ONCOLOGY GROUP,
已完成
不适用
PREDICTION OF RESPONSE AND TOXICITY IN PATIENTS WHO RECEIVE PACLITAXEL AND AVASTIN FOR BREAST CANCER. A CORRELATIVE, MULTICENTRIC, GENOMIC, PROTEOMIC AND PHARMACOGENIC STUDY-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-009-08HOSSIER ONCOLOGY GROUP,